• Pranav Sharma, Amber Malhotra, Sanjay Gandhi, Pankaj Garg, Arvind Bishnoi, and Hemang Gandhi.
• UN Mehta Institute of Cardiology and Research Center, Ahmedabad, Gujarat, India realpranav@yahoo.com.
• Asian Cardiovasc Thorac Ann. 2014 Jun 1; 22 (5): 539-45.

BackgroundLevosimendan is a new calcium sensitizing drug with vasodilatory and inotropic properties, which is used for the treatment of postoperative low cardiac output syndrome and difficult weaning from cardiopulmonary bypass.ObjectiveTo evaluate the hemodynamic effects of levosimendan during and after coronary artery bypass grafting on cardiopulmonary bypass and mitral valve repair in patients with low left ventricular ejection fractions (<30%).Methods40 patients were enrolled in this double-blind prospective randomized controlled trial. They received either levosimendan or a placebo preoperatively (n = 20) for 24 h. Clinical parameters were measured before and after administration. Any adverse events during and after drug administration and postoperative complications were evaluated.ResultsPatients treated with levosimendan exhibited a higher cardiac index and mean arterial pressure intraoperative and in the early postoperative period, compared to the control group. Patients treated with levosimendan required less ventilatory support (p < 0.0001) and had shorter intensive care unit (p < 0.0001) and hospital stay (p < 0.0001).ConclusionsPreoperative treatment with levosimendan in patients undergoing coronary artery bypass grafting and mitral valve repair resulted in improved hemodynamics and a stable postoperative course.© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

56 keywords...

hide…